Standard Protocol for Unfractionated Heparin Drip
For therapeutic anticoagulation in adults, initiate unfractionated heparin with an 80 U/kg IV bolus followed by 18 U/kg/hour continuous infusion, targeting an aPTT of 1.5-2.5 times control (approximately 50-70 seconds) or anti-factor Xa levels of 0.3-0.7 IU/mL. 1, 2
Initial Dosing
The weight-based dosing algorithm is the standard approach:
- Bolus dose: 80 U/kg IV push (maximum 4,000-5,000 units in some protocols) 1, 2
- Initial infusion rate: 18 U/kg/hour 1, 2
- Alternative for cardiovascular procedures: 50-70 U/kg bolus when GP IIb/IIIa inhibitors are planned 3
The FDA-approved labeling confirms these weight-based parameters for continuous IV infusion, with an initial 5,000 unit bolus followed by 20,000-40,000 units/24 hours (approximately 833-1,667 units/hour for a 70 kg patient) 2. However, the more precise weight-based approach of 80 U/kg bolus and 18 U/kg/hour is preferred by current guidelines 1.
Monitoring Protocol
Check aPTT approximately 4 hours after initiation, then every 4 hours initially until therapeutic, then at appropriate intervals (typically every 6-24 hours once stable). 2
Target Ranges:
- aPTT: 1.5-2.5 times control value (approximately 50-70 seconds) 1, 2
- Anti-factor Xa: 0.3-0.7 IU/mL (preferred when available) 1, 4
- Whole blood clotting time: 2.5-3 times control (less commonly used) 2
Dose Adjustment Nomogram:
The European Society of Cardiology provides a validated adjustment protocol 5:
- aPTT <35 seconds (<1.2× control): Give 80 U/kg bolus; increase infusion by 4 U/kg/hour 5
- aPTT 35-45 seconds (1.2-1.5× control): Give 40 U/kg bolus; increase infusion by 2 U/kg/hour 5
- aPTT 46-70 seconds (1.5-2.3× control): No change 5
- aPTT 71-90 seconds (2.3-3.0× control): Decrease infusion by 2 U/kg/hour 5
- aPTT >90 seconds (>3.0× control): Stop infusion for 1 hour, then decrease by 3 U/kg/hour 5
Safety Monitoring
Monitor platelet count every 2-3 days from day 4 to day 14 to screen for heparin-induced thrombocytopenia (HIT), which occurs in up to 5% of patients. 1
Additional monitoring includes:
- Baseline labs: aPTT, INR, platelet count, hemoglobin/hematocrit 2
- Ongoing: Hemoglobin/hematocrit and occult blood in stool periodically 2
- HIT surveillance: Look for ≥50% platelet drop, typically 5-10 days after starting heparin (earlier with prior exposure) 1
Important Clinical Considerations
When UFH is Preferred Over LMWH:
Despite guidelines preferring LMWH over UFH for VTE treatment (grade 2C) 1, UFH remains the anticoagulant of choice in specific situations:
- Severe renal failure (CrCl <30 mL/min) where LMWH accumulation is problematic 1, 6
- High bleeding risk requiring rapid reversibility with protamine 4
- Cardiovascular procedures requiring precise anticoagulation control 3, 2
- Extracorporeal circuits (dialysis, ECMO) 2
Common Pitfalls:
- Fixed dosing instead of weight-based: This leads to subtherapeutic or supratherapeutic levels 7, 8
- Inadequate initial bolus: Results in delayed time to therapeutic anticoagulation 8
- Failure to validate institutional aPTT assays: Different reagents produce different aPTT values for the same heparin level 1, 5
- Missing HIT surveillance: Can lead to catastrophic thrombotic complications 1
Special Populations:
Obese patients (>100 kg): Use actual body weight for dosing; both total body weight and adjusted body weight achieve similar therapeutic times and safety outcomes 9. The standard 80 U/kg bolus and 18 U/kg/hour infusion remain appropriate 9.
Elderly or high bleeding risk: Some institutions use lower intensity protocols (targeting anti-Xa 0.25-0.35 IU/mL), though this may increase bleeding without clear thrombotic benefit 10. Consider reducing initial infusion to 14 U/kg/hour in patients at very high bleeding risk 11.
Duration and Transition
Continue UFH for minimum 5 days when bridging to warfarin, overlapping until INR is 2-3 for two consecutive days. 12, 8, 2
For transition to direct oral anticoagulants, stop UFH infusion immediately after administering the first DOAC dose 2.
The therapeutic window is typically achieved within 24-48 hours using this protocol, with most patients reaching goal aPTT by 29 hours 9.